/Investor DB

Shenzhen Capital Group — 2021 Investments

2 investments dated 2021 · listed companies and verified rows first · show all

Beisenbeisen.comMay 2021 · $260M

HKSE-listed leader in AI-powered HCM solutions

Ji Weiguo(Founder)Wang Zhaohui(Founder)

Co-investorsGaocheng CapitalSoftBank Vision FundGenesis Venture CapitalGoldman SachsHongShan Capital GroupMatrix Partners China+3 more

Biohengbioheng.comMar 2021 · $80M

Imviva is a clinical-stage biotechnology company developing allogeneic CAR-T cell therapies for oncology and autoimmune diseases.

BiotechDeep TechHealthtechMedical Devices

Jiangtao Ren(Chief Scientific Officer)Lu Han(Chief Executive Officer)Yajin Ni(Chief Technology Officer)Jan Davidson(Chief Medical Officer)

Co-investorsDecheng CapitalGL VenturesHillhouse Capital

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.